Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Sep;4(5):607–610. doi: 10.1128/cdli.4.5.607-610.1997

Endotoxin-induced lethality in neonatal mice is counteracted by interleukin-10 (IL-10) and exacerbated by anti-IL-10.

F Nicoletti 1, G Mancuso 1, F A Ciliberti 1, C Beninati 1, M Carbone 1, S Franco 1, V Cusumano 1
PMCID: PMC170607  PMID: 9302214

Abstract

The lethal effects occurring in neonatal (<24-h-old) BALB/c mice after challenge with 25 mg of lipopolysaccharide (LPS) per kg of body weight were significantly counteracted by pretreatment with recombinant interleukin-10 (rIL-10; 25 or 50 ng/mouse). Concordantly, blockage of endogenous IL-10 with the SXC1 monoclonal antibody increased LPS-induced mortality. Both IL-10 and SXC1 modulated the release of tumor necrosis factor alpha (TNF-alpha) so that, relative to controls, peak TNF-alpha values after LPS challenge were decreased by rIL-10 and increased by anti-IL-10.

Full Text

The Full Text of this article is available as a PDF (165.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bean A. G., Freiberg R. A., Andrade S., Menon S., Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun. 1993 Nov;61(11):4937–4939. doi: 10.1128/iai.61.11.4937-4939.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cerami A. Tumor necrosis factor as a mediator of shock, cachexia and inflammation. Blood Purif. 1993;11(2):108–117. doi: 10.1159/000170104. [DOI] [PubMed] [Google Scholar]
  3. Cusumano V., Genovese F., Mancuso G., Carbone M., Fera M. T., Teti G. Interleukin-10 protects neonatal mice from lethal group B streptococcal infection. Infect Immun. 1996 Jul;64(7):2850–2852. doi: 10.1128/iai.64.7.2850-2852.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cusumano V., Mancuso G., Genovese F., Cuzzola M., Carbone M., Cook J. A., Cochran J. B., Teti G. Neonatal hypersusceptibility to endotoxin correlates with increased tumor necrosis factor production in mice. J Infect Dis. 1997 Jul;176(1):168–176. doi: 10.1086/514019. [DOI] [PubMed] [Google Scholar]
  5. Derkx B., Marchant A., Goldman M., Bijlmer R., van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis. 1995 Jan;171(1):229–232. doi: 10.1093/infdis/171.1.229. [DOI] [PubMed] [Google Scholar]
  6. Emerson T. E., Jr, Lindsey D. C., Jesmok G. J., Duerr M. L., Fournel M. A. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock. 1992 Oct;38(2):75–84. [PubMed] [Google Scholar]
  7. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  8. Florquin S., Amraoui Z., Abramowicz D., Goldman M. Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol. 1994 Sep 15;153(6):2618–2623. [PubMed] [Google Scholar]
  9. Genovese F., Mancuso G., Cuzzola M., Cusumano V., Nicoletti F., Bendtzen K., Teti G. Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Antimicrob Agents Chemother. 1996 Jul;40(7):1733–1735. doi: 10.1128/aac.40.7.1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Givner L. B., Gray L., O'Shea T. M. Antibodies to tumor necrosis factor-alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats. Pediatr Res. 1995 Oct;38(4):551–554. doi: 10.1203/00006450-199510000-00013. [DOI] [PubMed] [Google Scholar]
  11. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993 Apr 1;177(4):1205–1208. doi: 10.1084/jem.177.4.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ishida H., Hastings R., Thompson-Snipes L., Howard M. Modified immunological status of anti-IL-10 treated mice. Cell Immunol. 1993 May;148(2):371–384. doi: 10.1006/cimm.1993.1119. [DOI] [PubMed] [Google Scholar]
  13. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994 Jan 1;179(1):305–310. doi: 10.1084/jem.179.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jarvis W. R. Epidemiology of nosocomial infections in pediatric patients. Pediatr Infect Dis J. 1987 Apr;6(4):344–351. doi: 10.1097/00006454-198704000-00003. [DOI] [PubMed] [Google Scholar]
  15. Leonard E. M., van Saene H. K., Shears P., Walker J., Tam P. K. Pathogenesis of colonization and infection in a neonatal surgical unit. Crit Care Med. 1990 Mar;18(3):264–269. doi: 10.1097/00003246-199003000-00003. [DOI] [PubMed] [Google Scholar]
  16. Mancuso G., Cusumano V., Cook J. A., Smith E., Squadrito F., Blandino G., Teti G. Efficacy of tumor necrosis factor alpha and eicosanoid inhibitors in experimental models of neonatal sepsis. FEMS Immunol Med Microbiol. 1994 Jun;9(1):49–54. doi: 10.1111/j.1574-695X.1994.tb00473.x. [DOI] [PubMed] [Google Scholar]
  17. Mancuso G., Tomasello F., Migliardo M., Delfino D., Cochran J., Cook J. A., Teti G. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun. 1994 Nov;62(11):4997–5002. doi: 10.1128/iai.62.11.4997-5002.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Marchant A., Devière J., Byl B., De Groote D., Vincent J. L., Goldman M. Interleukin-10 production during septicaemia. Lancet. 1994 Mar 19;343(8899):707–708. doi: 10.1016/s0140-6736(94)91584-9. [DOI] [PubMed] [Google Scholar]
  19. Moore K. W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin-10. Annu Rev Immunol. 1993;11:165–190. doi: 10.1146/annurev.iy.11.040193.001121. [DOI] [PubMed] [Google Scholar]
  20. Standiford T. J., Strieter R. M., Lukacs N. W., Kunkel S. L. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol. 1995 Aug 15;155(4):2222–2229. [PubMed] [Google Scholar]
  21. Teti G., Mancuso G., Tomasello F. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun. 1993 Jan;61(1):227–235. doi: 10.1128/iai.61.1.227-235.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zeller W. P., Goto M., Witek-Janusek L., Hurley R. M. Mortality, temporal substrate and insulin responses to endotoxic shock in zero, ten and twenty-eight day old rats. Surg Gynecol Obstet. 1991 Nov;173(5):375–383. [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES